Blog Hero

Jetrea – New drug available

Book Appointment Online

Jetrea – Now Available

Jetrea is the first and only eye medicine to treat sight-threatening, symptomatic vitreomacular adhesion affecting an estimated 15,000 Canadians each year.

Vitreomacular adhesion occurs when the gel inside the eye starts to pull on the retina. In doing so, vision can be distorted or blurred. If patients are affected by this and it doesn’t resolve on its own, Jetrea can be injected by a retinal ophthalmologist.

Jetrea is an active enzyme that works to break down the protein fibres that cause the abnormal pull between the gel inside the eye and the retina.

Last evening, all the doctors at Abbey Eye Care attended a talk hosted by Alcon Canada and Dr. Varun Chaudhry. Dr. Chaudhry discussed the criteria that make certain patients candidates for this new medical treatment. Several case studies of actual patients that underwent treatment with Jetrea were also discussed.

Written by Jeff Goodhew

Dr. Goodhew graduated from the University of Waterloo with his Optometry degree in 1993 and became therapeutically licensed in 2000. He enjoys being an active part of his profession, having served as the President of the Ontario Association of Optometrists from 2014 through 2016. Dr. Goodhew also served as the co-chair of the National Public Education Committee for the Canadian Association of Optometrists.
instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star star-half chevron-right chevron-left chevron-down chevron-up envelope fax